Patients

Patients

Prostate cancer

Transform standard docetaxel therapy to benefit patients.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) is an advanced form of prostate cancer and the fourth most common cause of cancer death overall. mCRPC is resistant to surgical treatment or androgen deprivation therapy, an antihormone therapy used to prevent the growth of prostate cancer cells. IV docetaxel is currently the dominant form of chemotherapy used in mCRPC patients and is typically used in a first line setting in chemotherapy-naïve patients.

Modra has completed a Phase IIb clinical trial of ModraDoc006/r in patients with mCRPC, the results of which have been published in the European Journal of Cancer.

Clinical Trials

Clinical trials are voluntary research studies conducted in patients or healthy subjects, designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.

If you are interested in participating in a clinical trial, please speak with your physician to discuss whether this might be an option for you. Your doctor can also help answer questions about your type of cancer and clinical trials or other treatments that might be available to you. Your decision to participate in a clinical trial is voluntary and should be made only after all your questions have been answered and you are able to make a well-informed decision.

All Company therapeutic candidates described or mentioned herein are investigational and have not yet been approved for marketing by any regulatory authority.

ModraDoc006/r

A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.

This is a completed multicenter Phase IIb study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer, suitable for treatment with a taxane. More information is available at the clinicaltrials.gov website